Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
Phase 2
- Conditions
- Ischaemic Central Retinal Vein OcclusionNeovascular Glaucoma
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Gene Signal SAS
- Target Recruit Count
- 333
- Registration Number
- NCT02947867
© Copyright 2025. All Rights Reserved by MedPath